Equities

Virbac SA

Virbac SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)349.00
  • Today's Change2.50 / 0.72%
  • Shares traded7.20k
  • 1 Year change+14.61%
  • Beta0.7955
Data delayed at least 15 minutes, as of Apr 26 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Virbac SA is a France-based veterinarian pharmaceutical company that specializes in the development and production of vaccines and medicines for domestic animals and livestock. Its production centers are located in France, Australia, the United States, Mexico, Vietnam, Brazil and South Africa. Its development efforts focus mainly on formulating drugs designed to prevent or cure certain animal diseases. Its product portfolio encompasses pet medications such as pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds and rodents, as well as livestock medications including pest control drugs and antibiotics intended for cattle, sheep, pigs and poultry. It also offers food and electronic identification chips for pets.

  • Revenue in EUR (TTM)1.25bn
  • Net income in EUR121.30m
  • Incorporated1984
  • Employees5.46k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
VIRP:PAR since
announced
Transaction
value
Sasaeah Holdings Co LtdAnnounced06 Mar 202406 Mar 2024Announced4.49%303.94m
GS Partners SRODeal completed02 May 202302 May 2023Deal completed12.76%--
Data delayed at least 15 minutes, as of Apr 26 2024 16:35 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Boiron SA517.36m47.62m601.81m2.81k12.511.089.111.162.742.7429.7931.730.67921.366.57184,705.806.145.087.566.3973.8875.129.047.402.54--0.022548.8717.36-2.8656.44-10.60-19.01-7.22
Abivax SA0.00-147.74m927.57m40.00--4.73-----3.35-3.350.003.120.00----0.00-73.79-65.49-96.88-94.75-----------8.050.2206-------111.52---19.06--
Vetoquinol SA529.27m55.56m1.16bn2.48k20.872.2013.832.204.704.7044.7344.530.78762.395.74213,157.908.277.0910.449.4050.3158.8710.508.841.86--0.032418.39-1.957.5415.768.915.9812.11
Virbac SA1.25bn121.30m2.93bn5.46k24.133.2217.432.3514.3614.36147.65107.570.8941.307.94228,412.008.658.7012.1212.4464.9365.619.6710.211.0818.050.11667.212.537.49-0.528943.2612.08--
Ipsen SA3.31bn617.10m9.41bn5.33k15.192.439.832.857.397.7239.6646.250.5541.995.23620,920.2010.489.7113.9313.3382.7282.7618.9116.020.98930.430.08919.234.757.084.039.75-8.653.71
Eurofins Scientific SE6.51bn516.50m11.10bn61.80k22.032.179.801.702.611.3032.9226.440.621336.204.79105,417.605.417.496.709.3620.9323.788.7111.231.388.430.433219.28-2.9411.49-21.5310.918.5811.66
BioMerieux SA3.67bn357.60m11.78bn14.65k33.063.1319.113.203.013.0130.9331.760.70361.975.00250,815.606.189.307.8812.3155.9956.518.7812.381.19--0.121517.762.398.70-20.956.878.3619.42
Data as of Apr 26 2024. Currency figures normalised to Virbac SA's reporting currency: Euro EUR

Institutional shareholders

11.63%Per cent of shares held by top holders
HolderShares% Held
Grandeur Peak Global Advisors LLCas of 31 Jan 2024167.26k1.98%
The Vanguard Group, Inc.as of 05 Apr 2024155.89k1.84%
Oddo BHF Asset Management SASas of 28 Mar 2024116.14k1.37%
Financi�re de l'�chiquier SAas of 31 Mar 2023107.08k1.27%
Norges Bank Investment Managementas of 31 Dec 2023106.65k1.26%
T. Rowe Price International Ltd.as of 31 Mar 202474.81k0.88%
Lazard Fr�res Gestion SASas of 29 Sep 202371.21k0.84%
Allianz Global Investors GmbHas of 31 Dec 202364.21k0.76%
Amundi Asset Management SA (Investment Management)as of 03 Apr 202461.48k0.73%
BlackRock Fund Advisorsas of 04 Apr 202459.29k0.70%
More ▼
Data from 31 Dec 2023 - 17 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.